Plecanatide
Also known as: Trulance, SP-304
Plecanatide is a synthetic guanylate cyclase-C agonist peptide that mimics the action of endogenous uroguanylin to increase fluid secretion in the intestines. This FDA-approved peptide treats chronic idiopathic constipation and irritable bowel syndrome with constipation by activating cGMP signaling pathways in intestinal epithelial cells.
Plecanatide is a 1,682 Da research peptide. Plecanatide is a synthetic guanylate cyclase-C agonist peptide that mimics the action of endogenous uroguanylin to increase fluid secretion in the intestines. This FDA-approved peptide treats chronic idiopathic constipation and irritable bowel syndrome with constipation by activating cGMP signaling pathways in intestinal epithelial cells.
Also called: Trulance, SP-304
1,682
Molecular Weight
Daltons
4
Strong Evidence
benefits
4
Studies Cited
peer-reviewed
3-3
Typical Dose
mg
Overview
Plecanatide represents a targeted therapeutic approach for gastrointestinal disorders characterized by constipation. As a 16-amino acid synthetic analog of human uroguanylin, plecanatide binds specifically to guanylate cyclase-C receptors on the luminal surface of intestinal epithelial cells. This binding triggers increased cyclic guanosine monophosphate (cGMP) production, which activates protein kinase G and the cystic fibrosis transmembrane conductance regulator (CFTR). The result is enhanced chloride and bicarbonate secretion into the intestinal lumen, followed by sodium and water efflux that softens stool and accelerates transit. Unlike systemic laxatives, plecanatide acts locally within the gastrointestinal tract with minimal systemic absorption, reducing the risk of electrolyte imbalances and dependency. Clinical trials demonstrate consistent efficacy in improving bowel movement frequency, stool consistency, and patient-reported outcomes in chronic constipation and IBS-C populations.
Key Takeaways: Plecanatide
- Strongest evidence supports Plecanatide for chronic idiopathic constipation relief and ibs-c symptom management
- Research doses typically range from 3 to 3 mg via oral
- 4 benefits with strong evidence, 2 moderate, 0 preliminary
- Half-life: Not applicable (minimal systemic absorption)
- 4 cited research studies in this guide
Mechanism of Action
Plecanatide selectively binds to guanylate cyclase-C receptors on intestinal epithelial cells, mimicking endogenous uroguanylin. This binding increases intracellular cGMP levels, activating protein kinase G and subsequently opening CFTR chloride channels. The resulting chloride and bicarbonate efflux draws sodium and water into the intestinal lumen, increasing fluid content and promoting bowel movements. The peptide remains active in the harsh intestinal environment due to its cyclic structure and disulfide bonds, which confer resistance to proteolytic degradation.
Research Benefits
Plecanatide at a Glance
Plecanatide selectively binds to guanylate cyclase-C receptors on intestinal epithelial cells, mimicking endogenous uroguanylin.
Chronic Idiopathic Constipation Relief
Strong EvidenceIncreases spontaneous bowel movements and improves stool consistency through targeted guanylate cyclase-C activation, with clinical trials showing significant improvement in bowel movement frequency within the first week of treatment.
IBS-C Symptom Management
Strong EvidenceReduces abdominal pain, bloating, and straining associated with irritable bowel syndrome with constipation by normalizing intestinal fluid secretion and accelerating colonic transit time.
Improved Stool Consistency
Strong EvidenceSoftens hard, lumpy stools by increasing water content in the intestinal lumen, making bowel movements easier and less painful without causing loose stools or diarrhea at therapeutic doses.
Local Intestinal Action
Strong EvidenceProvides therapeutic benefits with minimal systemic exposure, reducing the risk of electrolyte disturbances and drug interactions compared to osmotic or stimulant laxatives.
Enhanced Quality of Life
Moderate EvidenceClinical assessments demonstrate significant improvements in patient-reported outcomes including reduced straining, increased satisfaction with bowel habits, and decreased constipation-related anxiety.
Sustained Efficacy
Moderate EvidenceMaintains therapeutic effects over long-term treatment periods without tolerance development or rebound constipation upon discontinuation, as demonstrated in extended clinical trials.
Research Dosing Protocols
Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
| Research Protocol | Dose Range | Route |
|---|---|---|
| Chronic idiopathic constipation | 3–3 mg | oral |
| IBS-C management | 3–3 mg | oral |
| Dose-response studies | 1–9 mg | oral |
Frequency
Once daily
Timing
With or without food, preferably at the same time each day
Cycle Length
Continuous use as needed for symptom management
Research Notes
- 1Should be taken with adequate fluid intake
- 2Effects typically begin within 1-2 days of initiation
- 3Dose adjustment not required for mild to moderate renal or hepatic impairment
- 4Discontinue if severe diarrhea develops
Reconstitution Guide
Standard Reconstitution
Vial Size
0 mg
Bacteriostatic Water
0 mL
Concentration
NaN mcg
per 0.1 mL (10 units)
Step-by-Step Guide
Gather Materials
Plecanatide vial, bacteriostatic water, alcohol swabs, insulin syringes.
Equilibrate Temperature
Remove the vial from storage and allow it to reach room temperature (5-10 minutes).
Sanitize
Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.
Draw Water
Draw 0 mL of bacteriostatic water into a syringe.
Add Water to Vial
Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.
Mix Gently
Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.
Store Properly
Refrigerate at Room temperature (20-25°C). 36 months from manufacture date.
Storage Temperature
Room temperature (20-25°C)
Shelf Life
36 months from manufacture date
Important Notes
- •Available as immediate-release oral tablets
- •Store in original container to protect from moisture
- •Do not crush or chew tablets
- •Not applicable for injection - oral formulation only
Plecanatide Dosing Calculator
Calculate daily intake, cycle totals, and vials needed with pre-filled protocols →
Plecanatide Reconstitution Calculator
Calculate concentration, syringe units, and doses per vial with auto-filled values →
Safety & Side Effects
Reported Side Effects
- !Diarrhea (most common, usually mild to moderate)
- !Abdominal pain or cramping
- !Flatulence and abdominal distension
- !Nausea and vomiting
- !Upper respiratory tract infections
- !Headache
- !Abdominal tenderness
- !Dehydration (with severe diarrhea)
- !Electrolyte imbalance (rare, with excessive fluid loss)
- !Rectal bleeding (rare)
Potential Interactions
- ⚡Antacids may reduce absorption if taken simultaneously
- ⚡Proton pump inhibitors may alter intestinal pH affecting efficacy
- ⚡Antibiotics affecting gut microbiome may influence response
- ⚡Other laxatives may increase risk of excessive fluid loss
- ⚡Anticholinergic medications may counteract prokinetic effects
Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.
Research Studies
The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.
Efficacy and Safety of Plecanatide in Patients with Chronic Idiopathic Constipation
Phase 3 randomized trial of 1,394 patients showing plecanatide 3mg significantly increased spontaneous bowel movements and improved stool consistency compared to placebo over 12 weeks.
Plecanatide for the Treatment of Irritable Bowel Syndrome with Constipation
Two phase 3 trials (n=2,741) demonstrated plecanatide significantly improved IBS-C symptoms including abdominal pain and bowel movement frequency over 26 weeks.
Long-term Safety and Efficacy of Plecanatide in Chronic Idiopathic Constipation
Open-label extension study showing sustained efficacy and safety of plecanatide over 15 months in 768 patients with chronic constipation.
Pharmacokinetics and Mass Balance of Plecanatide Following Oral Administration
Study demonstrating minimal systemic absorption (<0.1%) and predominantly fecal elimination of plecanatide, supporting its local mechanism of action.
Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.
Frequently Asked Questions
Most patients experience increased bowel movement frequency within 1-2 days of starting plecanatide. Full therapeutic benefits for stool consistency and reduced straining typically develop within the first week of daily use.
Yes, plecanatide can be taken with or without food. Food does not significantly affect its absorption or efficacy. Take it at the same time each day for best results.
Mild diarrhea is the most common side effect and often resolves as your body adjusts. Stay hydrated and contact your healthcare provider if diarrhea becomes severe, persistent, or causes dehydration symptoms.
No, plecanatide does not cause dependency or tolerance. It works by mimicking natural intestinal hormones rather than artificially stimulating the bowel. You can stop taking it without experiencing rebound constipation.
Avoid plecanatide if you have known or suspected mechanical gastrointestinal obstruction, inflammatory bowel disease, or severe diarrhea. Patients under 18 years old should not use plecanatide due to safety concerns.
Combining plecanatide with other laxatives may increase the risk of diarrhea and fluid loss. Discuss all constipation treatments with your healthcare provider to avoid excessive bowel stimulation.
Plecanatide works by increasing intestinal fluid secretion through specific cellular receptors, providing faster relief than fiber supplements. Unlike fiber, plecanatide doesn't require a gradual dose increase and works regardless of dietary fiber intake.
Plecanatide is approved for chronic constipation lasting at least 3 months. For occasional constipation, shorter-acting treatments may be more appropriate. Consult your healthcare provider for guidance on treatment duration.
Research & Educational Use Only
All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.
The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.